Technology ID
TAB-4884
Advancements in RSV Vaccine Development for Enhanced Immune Response
E-Numbers
E-067-2016-0
Lead Inventor
Collins, Peter
Lead IC
NIAID
Co-Inventors
Buchholz, Ursula
ICs
NIAID
Applications
Vaccines
Therapeutics
Therapeutic Areas
Respiratory
Infectious Disease
Development Stages
Clinical Phase I
Research Products
Research Equipment
Antibodies
This technology presents a groundbreaking approach to developing a vaccine for Respiratory Syncytial Virus (RSV), a major cause of severe pediatric respiratory illness. The method involves the creation of a live attenuated RSV vaccine candidate by removing the M2-2 protein, resulting in decreased viral replication. Surprisingly, this modification induces a stronger immune response. The vaccine, derived from LID M2-2 with minor mutations, effectively separates viral replication from immunogenicity. Initial results suggest that children who received this vaccine produced anti-RSV antibodies without experiencing severe illness during subsequent RSV seasons, highlighting its potential to provide protection against RSV infection.
Commercial Applications
The potential applications of this RSV vaccine technology extend beyond addressing severe respiratory illness in young children. Its unique approach, which separates viral replication from immunogenicity, may have broader implications, potentially revolutionizing vaccine development strategies for other infectious diseases. Furthermore, it could contribute to advancements in immunology and innovative vaccine design, ultimately benefiting public health.
Competitive Advantages
The competitive advantage of this RSV vaccine technology lies in its ability to induce a stronger immune response while limiting viral replication. By removing the M2-2 protein, it enhances safety and effectiveness, reducing the risk of vaccine-induced illness. This unique approach sets it apart from previous candidates, making it a promising solution for combating RSV in young children.
Licensing Contact: